Dominant mutations in the valosin-containing protein ( VCP ) gene cause inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia, which is characterized by progressive muscle weakness, dysfunction in bone remodeling, and frontotemporal dementia. More recently, VCP has been linked to 2% of familial amyotrophic lateral sclerosis cases. VCP plays a signifi cant role in a plethora of cellular functions including membrane fusion, transcription activation, nuclear envelope reconstruction, postmitotic organelle reassembly, and cell cycle control. To elucidate the pathological mechanisms underlying the VCP disease progression, we have previously generated a VCP R155H/+ mouse model with the R155H mutation. Histological analyses of mutant muscle showed vacuolization of myofi brils, centrally located nuclei, and disorganized muscle fi bers. Global expression profi ling of VCP R155H/+ mice using gene annotations by DAVID identifi ed key dysregulated signaling pathways including genes involved in the physiological system development and function, diseases and disorders, and molecular and cellular functions. There were a total of 212 signifi cantly dysregulated genes, several of which are involved in the regulation of proteasomal function and NF-κ B signaling cascade. Findings of the gene expression study were validated by using quantitative reverse transcriptase polymerase chain reaction analyses to test genes involved in various signaling cascades. This investigation reveals the importance of the VCP R155H/+ mouse model in the understanding of cellular and molecular mechanisms causing VCP-associated neurodegenerative diseases and in the discovery of novel therapeutic advancements and strategies for patients suffering with these debilitating disorders. Clin Trans Sci 2015; Volume 8: 8-16
Introduction
Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD, OMIM 167320) is characterized by progressive muscle weakness, bone deformities, and premature dementia. 1 Eighty-two percent of patients manifest weakness and atrophy of the pelvic and shoulder girdle muscles at the mean age of 42 years. [1] [2] [3] [4] During disease progression, muscle weakness is also seen in other muscles including limb and respiratory muscles, whereas cardiac failure as well as cardiomyopathy has been observed in later stages. Th e diagnosis of IBMPFD muscle disease is based on clinical fi ndings including elevated serum creatinine kinase (CK) concentration myopathic electromyograms and skeletal muscle histology fi ndings of rimmed vacuoles and inclusion bodies, which stain positive for ubiquitin and TAR DNA-binding protein-43 (TDP-43) antibodies. 1, [4] [5] [6] Paget's disease of bone (PDB) seldom aff ects individuals under the age of 50 years. However, early-onset PDB is observed in 49% of IBMPFD patients. 1, 3 It typically begins in the 30s to 40s, at a mean age of onset of 42 years. PDB is caused by excessive osteoclastic activity and susceptibility to deformities like bowing and fractures. It involves focal areas of increased bone turnover that typically leads to spine and/or hip pain and deformity of the long bones causing pathological fractures on occasion. Th e most commonly involved bones are the skull, vertebrae, and pelvis. Th e diagnosis of PDB is based on elevated concentrations of serum alkaline phosphatase, urine pyridinoline, and deoxypyridinoline, as well as on skeletal radiographs or radionuclide scans. 7, 8 Frontotemporal dementia (FTD) comprises about 3% of dementias of the elderly. [9] [10] [11] In IBMPFD, premature FTD is observed in 30% of patients with an average age of onset in the mid-50s. It is characterized by dysnomia, dyscalculia, comprehension defi cit, paraphasic errors, and relative preservation of memory. In later stages, patients have auditory comprehension defi cits for even one-step commands, and exhibit alexia and agraphia. 1, 3 Aff ected individuals die from progressive muscle weakness, as well as from cardiac and respiratory failure typically in their 40s to 60s. 1, [2] [3] [4] IBMPFD is caused by mutations in the valosin-containing protein ( VCP ) gene, 5 and more than 31 disease mutations have been identifi ed to date (for review, see Kimonis et al. 4 ). VCP belongs to the family of type II ATPase associated with variety of cellular activities (AAA) having two ATPase domains. [12] [13] [14] [15] [16] It has been suggested to be involved in several cellular activities including homotypic membrane fusion, transcription activation, nuclear envelope reconstruction, postmitotic organelle reassembly, cell cycle control, apoptosis, and endoplasmic reticulum-associated degradation of proteins. [17] [18] [19] [20] Disease mutations cluster in the N-terminal CDC48 domain, which is involved in ubiquitinbinding and protein-protein interactions. 21, 22 Most of these mutated residues causing IBMPFD are three-dimensionally located in a close proximity and potentially interact with each other. Th ese fi ndings suggest that these residues may have a similar and specifi c function within the VCP homohexamer, which binds to several diff erent adapter proteins enabling VCP to target specifi c substrates for proteasomal degradation. 23, 24 In order to investigate the in vivo eff ects of identifi ed VCP mutations, as well as to understand the pathogenesis of IBMPFD, mouse models have been generated. Both human and mouse VCP proteins consist of 806 amino acids, and the mouse protein diff ers only by one amino acid residue at position 684 when compared to the corresponding human protein. 25 Targeted homozygous deletion of VCP by Cre-loxP technology was reported to result in early embryonic lethality, 26 suggesting an important role 9 VOLUME 8 • ISSUE 1 WWW.CTSJOURNAL.COM for the intact VCP expression in the development of mouse embryos. In contrast, heterozygous mice lacking one VCP allele were indistinguishable from their WT littermates. On the other hand, transgenic mice overexpressing the most common human IBMPFD mutation, R155H, under the regulation of a muscle CK promoter demonstrated progressive muscle weakness in a dosedependent manner starting at 6 months of age. 27 Th ese mutant mice showed muscle pathology including coarse internal architecture, vacuolization, and disorganized membrane morphology. Also, the level of ubiquitinated protein inclusions was increased even before animals displayed measurable muscle weakness. Th ese results indicate that the phenotype of the generated transgenic mouse model resemble the VCP-associated disease pathology.
We have previously performed expression profi les using Human Genome Array microarray technology in Vastus lateralis muscles from patients and their fi rst-degree relatives. 28 Genes that were diff erentially expressed in the patients' muscle were analyzed using gene pathways. Th e global microarray analyses conducted revealed dysregulation mainly of the genes involved in the actin cytoskeleton cascade, involving several critical growth factor receptors, such as FGFR2 and EGFR; and disruption of the autophagy pathway genes, namely ATG4A, mTOR, and FoxO3. 28 Th e signaling intermediates involved in these pathways are known to be important for the crosstalk between protein breakdown and synthesis in IBMPFD disease. Here, we report the fi rst study to investigate the global microarray expression analysis of the VCP R155H/+ murine model for comparison with human VCP-associated disease. Th e mice express the mutant VCP at an endogenous level in the correct location of the mouse genome, and therefore, they are believed to represent an ideal model to study the pathology of the disease. It was hoped that by studying mice we might be able to overcome the variation between individuals with VCP disease. Our analyses revealed that VCP R155H/+ mutant mice demonstrate dysregulated genes and cascades which may aid to study the pathological molecular mechanisms underlying VCP-associated diseases in patients.
Methods

Generation and validation of VCP R155H/+ mice
Mouse genomic VCP fragment with 7.9 kb of upstream homology sequence and 2.1 kb of downstream homology sequence was subcloned into a targeting vector. Site-directed mutagenesis using Quick-Change XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) was used to introduce the R to H mutation at amino acid position 155. Th e VCP R155H/+ mouse model with the R155H VCP mutation was generated at the inGenious Targeting Laboratory, Inc. (Stony Brook, NY, USA), as described previously. 29 All experiments were done with the approval of the Institutional Animal Care and Use Committee (IACUC Protocol #2007-2716-2) of the University of California, Irvine (UCI), and in accordance with the guidelines established by the NIH. All animals were housed in the vivarium of the UCI and maintained under constant temperature (22°C) and humidity with a controlled 12:12-hour light-dark cycle. Mice had free access to mouse chow (Harlan Teklad Rodent Diet, Madison, WI, USA) and 0.9% NaCl drinking water ad libitum . Mice were euthanized by CO 2 inhalation followed by cervical dislocation for all experiments. For PCR genotyping, tail clips were obtained and sent to Transnetyx, Inc. (Cordova, TN, USA) and analyzed by our laboratory. To follow the development of body mass, the weight of every VCP R155H/+ and WT mouse was measured weekly. Motor coordination and fatigue were assessed by Rotarod testing (Med Associates Inc., St. Albans, VT, USA) accelerating speed analysis and muscle strength of the forelimbs of mice was measured by using a Grip Strength Meter apparatus (TSE Systems Gmbh, Hamburg, Germany). 29
Histological analyses
Th e histopathology of VCP R155H/+ mice was analyzed by hematoxylin and eosin (H&E) staining, immunohistochemistry, and electron microscopy. Ten-month-old mice (three WT and three VCP R155H/+ ) were euthanized by cervical dislocation, dissected quadriceps and brain tissues were mounted in a cryosectioning mounting media (Electron Microscopy Sciences, Hatfi eld, PA, USA) and stored at -80°C before sectioning at 5-10 μ m. For H&E staining, cryosections were fi xed in 10% formalin for 30 minutes and washed three times with PBS. Th ereaft er, sections were incubated in hematoxylin/glacial acetic acid (Sigma-Aldrich, St. Louis, MO, USA) solution for 3 minutes, rinsed with deionized water for 5 minutes, dipped 8-12 times into acid ethanol, rinsed two times for 1 minute with tap water, and once with deionized water for 2 minutes. Th ereaft er, slides were stained with eosin for 30-45 seconds, incubated in 95% ethanol three times for 5 minutes, three times in 100% ethanol for 5 minutes, and fi nally three times in xylene for 15 minutes. Slides were mounted with Permount (Fisher Scientifi c, Pittsburgh, PA, USA) and results were analyzed by a light microscope (Carl Zeiss, Oberkochen, Germany) using an AxioVision image capture system as described previously. 30
Gene expression profi ling
For comparative gene expression profi ling, quadriceps muscle samples from three 10-month-old WT and R155H mice were frozen in liquid nitrogen and homogenized. Total RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) following manufacturer's instructions. RNA extractions were further purifi ed by passage through RNeasy minicolumns (Qiagen, Valencia, CA, USA) according to the manufacturer's protocols for RNA cleanup. Final RNA preparations were resuspended in RNase-free water and stored at 80°C. Th e quality of RNA was assessed by Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) monitoring for the S28/S18 ratio and signs for degradation. Concentrations were measured by spectrophotometry. An aliquot of 2 μ g of total high-quality RNA from each sample was used to generate cDNA containing an initiation site for T7 RNA polymerase. cDNA synthesis and in vitro transcription reactions were performed using Aff ymetrix GeneChip Expression 3' Amplifi cation One-Cycle Target Labeling and Control Reagent kit according to manufacturer's instructions (Aff ymetrix, Santa Clara, CA, USA). Double-stranded cDNA and Biotinylated cRNA were purifi ed by Gene Chip Sample Cleanup Module (Aff ymetrix). An aliquot of 17 μ g of biotinylated cRNAs from samples were fragmented in 1 x fragmentation buff er (40 mM Tris-acetate, pH 8.1, 100 mM KOAc, 30 mM MgOAc) at 94°C for 35 minutes, of which 1 μ L was subjected to an analysis on 1% agarose gel. Ten μ g of biotinylated and fragmented cRNA was hybridized to Mouse Genome 430 2.0 arrays (Aff ymetrix) for 16 hours. Th e arrays were washed and stained on the Aff ymetrix Fluidics Station 450, using instructions and reagents provided by Aff ymetrix. Signal intensity was amplifi ed by second staining with biotin-labeled antistreptavidin antibody followed by phycoerythrin-streptavidin restaining. Fluorescent images were captured using the Aff ymetrix Gene Chip Scanner 3000 7G.
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Microarray data analysis
Expression values were calculated using the Probe Logarithmic Intensity Error Estimation (Aff ymetrix) algorithm. Hierarchical clustering analysis of that data set was performed using the Hierarchical Clustering Explorer 3, 31 which shows how samples are clustered, and allows eliminating suspicious samples from the analyses after checking them on contents of fatty and fi brosis tissue. A gene list of statistically signifi cant up-and down-regulated genes with p-values <0.01 was generated with Gene Spring GX version 7.3.1. (Agilent Technologies), using ANOVA (Welch, t -test) with standard operating procedures and quality controls. Normalized signals were calculated using Probe Logarithmic Intensity Error, and SDK Version 2 (Aff ymetrix). CEL-processed image fi les were analyzed for that probe set algorithm.
Q-real-time polymerase chain reaction (Q-RT-PCR) analysis
Gene expression analyses were performed with the Real-Time system to simultaneously quantify both rare and abundant genes in the same sample. A two-step approach was used in which the initial reverse transcription was followed by RT-PCR amplifi cation. 
Results
VCP R155H/+ mice share similar histopathological features with human patients
Progressive muscle weakness is one of the leading symptoms in human IBMPFD patients. 4 Histological analyses of muscle tissues from IBMPFD patients have revealed that patients' tissues accumulate enlarged vacuoles as well as ubiquitin-and TDP-43positive inclusion bodies. 6 Similar inclusion pathology has also been reported in patients' brain, including neocortex, as well as in limbic and subcortical nuclei. 32, 33 Th e VCP R155H/+ mice quadriceps depict enlarged vacuoles and centrally located nuclei ( Figure 1 ) and have been fully characterized as described previously. 29, 30 Expression profiling identifies differentially expressed pathways and genes To obtain some understanding of the consequences of the global gene expression in the mutant skeletal muscle, comparative gene expression profi ling was performed in the quadriceps muscle of 10-month-old WT and VCP R155H/+ mice. Th e global expression profi ling was performed using Mouse genome 430 2.0 arrays, which have more than 45,000 probe sets. To avoid the infl uence of estrogen cycle on the expression results, only male mice were selected for the analyses. Signifi cant changes in expression levels were found altogether for 212 genes with p < 0.01, 172 of which were up-regulated and 40 down-regulated. Th irty-nine genes depicted more than a 1.8-fold change in expressions, 28 of which were up-regulated and 11 down-regulated when compared to their WT littermates ( Table 1 ). Four genes showed up-regulation of >3-fold (killer cell lectin-like receptor, T-cell receptor beta, and two unknown transcripts) and six genes showed down-regulation of >3-fold (SRY-box-containing gene 12, SLAM family member 8, and 4 unknown transcripts).
To elucidate the biological processes associated with the observed transcriptional profi les, Ingenuity Pathway analysis (Aff ymetrix) was applied to dysregulated genes with highly signifi cant diff erences (p < 0.01) between WT and VCP R155H/+ samples. Th e physiological system development and function (endocrine system development and function, nervous system development and function, tissue development, embryonic development, hematological system development and function) contained 31% of the dysregulated genes, 27.9% of genes were associated with diseases and disorders (genetic disorders, neurological diseases, respiratory diseases, renal and urological diseases, developmental disorders), and 26% of dysregulated genes were associated with diff erent molecular and cellular functions (molecular transport, small molecule biochemistry, lipid metabolism, cell-to-cell signaling and interaction, and carbohydrate metabolism; Table 2 ). Further analyses revealed several genes within these biological processes showing diff erences in expression levels between WT and VCP R155H/+ mice, although not all of these changes reached the >1.8-fold cutoff level (data not shown). Finally, we generated Ingenuity networks using dysregulated genes in the quadriceps samples from R155H mice. Network 1 included 24 dysregulated genes with score 49 (amino acid metabolism, molecular transport, small molecule biochemistry). Network 1 includes several diff erentially expressed genes, which are involved in the regulation of signaling pathways, NF-κ B and ERK, as well as proteasomal function cascades ( Figure 2 ). Network 2 included 13 genes with score 21 (cellular development, nervous system, development and function, cellular growth and proliferation), 12 genes belonged to network 3 with score 20 (developmental disorder, genetic disorder, cell cycle), 12 genes belonged to network 4 with score 20 (cellular assembly and organization, cellular function and maintenance, endocrine system development and function), and 12 dysregulated genes belonged to network 5 with score 20 (lipid metabolism, molecular transport, small molecule biochemistry).
Ingenuity pathway analysis of 212 dysregulated genes with p < 0.01 from the quadriceps muscle of R155H knock-in mice 
Physiological system development and function
Verifi cation of dysregulated genes
Findings of the gene expression study were validated by using quantitative reverse transcriptase polymerase chain reaction analyses to test genes involved in various signaling cascades ( Figure 3 ; Table 3 ). Th ese genes S100A3 (S100 calcium-binding protein A3, up- Figure 3 ).
Comparison of mouse and human microarray data
Corelations were performed between the altered genes in the mouse and human muscle studies. In view of the similarity of histopathological features in the VCP R155H/+ mice and VCP patients, we compared the results from the mouse studies with microarray studies in muscle as reported by Nalbandian et al. (2012) . 28 Pathways that were modifi ed in humans with VCP disease included regulation of actin cytoskeleton, ErbB signaling, cancer, in addition to regulation of autophagy and lysosomal signaling 28 and in heterozygous mice proteasomal and NF-κ B signaling as well as genes involved in physiological system development and function. Common genes from both human and mouse studies included: TROAP, F2RL2, GLI2 PHOX2A ANKRD10, and MMD2, and we did not fi nd a consistent pattern across genes that depicted common trends of dysregulation (data not shown).
Discussion
VCP is involved in a number of cellular functions, most of which are related to ubiquitin-proteasome-dependent proteolysis of proteins that is mediated by interaction with ubiquitinated polypeptide substrates. 21, [34] [35] [36] [37] It is highly conserved in evolution suggesting that it is essential for normal cellular functions by playing a fundamental role within both unicellular (yeast) and multicellular organisms. [38] [39] [40] More recently, VCP mutations have been implicated in causing fALS cases. Th ese observations, as well as the fi nding that inhibition of VCP expression promotes apoptosis, 41 suggest that intact VCP is indispensable for normal development and cell survival. Despite intense investigations, the disease molecular mechanisms underlying VCP-associated diseases remain to be clarifi ed.
To further elucidate tissue and cellular pathology of IBMPFD, we generated and characterized the VCP R155H/+ murine model of VCP-associated diseases. 29 Th e heterozygous mutation did not aff ect the fertility or viability of mice since mutant and WT mice were born in Mendelian ratio. Th ese observations also revealed that the more mutant VCP molecules are added to hexamers the more the complex functioning is aff ected resulting eventually in totally nonfunctional protein complexes. Th ese defi ciencies in hexameric functions cannot be compensated by other molecules or protein complexes, which lead to lethality already in embryogenesis. Findings of the gene expression study were validated by using quantitative reverse transcriptase polymerase chain reaction analyses to test genes involved in various signaling cascades (S100A3, KLRA, ITGA, LRP8, CORO1A, and SLAMf8) . Although body weight and daily activities of heterozygous VCP R155H/+ mice were not seen to diff er from those of WT mice, mutant mice demonstrated several phenotypic and histological changes, all of which are typical of human IBMPFD patients. Muscle strength of forelimbs showed progressive deterioration when measured by grip strength test. Similar progressive weakness has been reported in patients 1, 2, 42 and transgenic mice expressing VCP R155H/+ . 43 Consistently with the transgenic mice and human patients, Badadani et al. (2010) 29 demonstrated that the VCP R155H/+ mice did not exhibit weakness in early adulthood (3 months), but only in the later stage of development (from 6 months onward) showing progressive deteriorating of muscle strength. 29 Physical performance was also decreased in these VCP R155H/+ mice when tested by Rotarod, further suggesting that the R155H mutation results in accelerated fatigue due to decreased muscle strength. Although no cerebellar dysfunction has been reported in IBMPFD patients, we cannot exclude the possibility of the involvement of defects in the cerebellum of mutant mice because Rotarod also measures the coordination of physical performance, which is controlled by cerebellum, in addition to muscular fatigue. Watts et al. (2007) 27 reported severe degeneration of hippocampal region in a postmortem examination of a patient who died at age 52 years, 27 and Forman et al. (2006) 32 found striking atrophy of the hippocampus in a patient with the R155H mutation. Th ese fi ndings combined with the observation that VCP is abundantly expressed in hippocampus 44 propose an important role for VCP in the proper functioning of this brain region, and encourage us to begin more detailed studies of IBMPFD brain focusing on the hippocampal regions. Previous histological analyses, immunohistochemistry, and electron microscopy has shown vacuolization as well as accumulation of ubiquitin-and TDP-43-positive inclusions in muscle fi bers from the quadriceps of VCP R155H/+ mice. Histological analyses of IBMPFD muscle biopsies have shown similar TDP-43-and ubiquitin-positive sarcoplasmic inclusions 6 suggesting that the muscle histopathology of the generated knock-in mouse model closely resembles that of human IBMPFD patients. Th ese results were consistent with those obtained from the analyses of R155H transgenic mice showing ubiquitin-positive inclusions bodies. 43 VCP R155H/+ mouse muscle also demonstrated increased number of regenerating muscle fi bers, which were identifi ed by central nucleation. Although the mutant muscle clearly showed similar defects to human patients, the brain histology of VCP R155H/+ mice seemed to be indistinguishable from the staining patterns of their WT littermates. Th is may be due to the young age of the mice analyzed (10 months of age). Eighty-seven percent of patients develop muscle weakness at the mean age of 42 years, whereas only 27% of patients develop FTD at the mean age of 57 years. 4 Th erefore, it is likely that brain pathology of VCP R155H/+ mice is not histologically detectable before mutant mice reach the age of 18 to 24 months.
Affy ID Fold change p value Common name Genbank
Muscle damage was further confi rmed by electron microscopic studies of the VCP R155H/+ muscle. Myofi lament structures showed disorganization and vacuolization as well as abnormally swollen mitochondria, which is a typical feature of pathophysiological processes [45] [46] [47] and suggests that energy metabolism of aff ected muscle may be disturbed. It can also be assumed that observed increased autophagosome formation in mutant muscle tissue plays a role in muscular dysfunction and cell death. Autophagy is a process that functions as a stress response that is up-regulated by starvation, oxidative stress, or other harmful conditions. It plays a role in programmed cell death and possesses important housekeeping and quality control functions that contribute to health and longevity (for review, see Bergamini et al., 48 Galluzzi et al., 49 and Scarlatti et al. 50 ). In addition, impaired autophagic degradation contributes to the pathogenesis of several human diseases including muscle diseases and lysosomal storage disorders. Danon disease is an example of a human myopathy that is characterized by accumulation of autophagic vacuoles in the heart and skeletal muscle. 51 Mouse model for the disease exhibits similar histological and phenotypic features to human patients showing massive accumulation of autophagic vacuoles in several tissues, including skeletal muscle and heart. 52 Mitochondria is a main target for autophagic degradation in muscle diseases resulting in reduced mitochondrial function, which leads to defective energy metabolism and reduced contractility. 53 Th erefore, increased autophagosome formation in VCP R155H/+ mice may be involved in the increased apoptosis and muscle weakness, which can be due to aff ected lysosomes-autophagosome fusion or impaired autophagosome function.
Gene expression profi ling of the VCP R155H/+ mice revealed changes on the steady state expression level for several genes that are involved in ubiquitin-proteasome system. Th e up-regulation of these genes (RGS7/regulator of G protein signaling 7, ELK3/ member of ETS oncogene family, IKBKG/inhibitor of kappaB kinase gamma, CENPA/unknown transcript) is of great interest because the main function of VCP is believed to be the translocation of defective proteins to proteasomes. Th ese results suggest that proteasome-related proteins attempt to compensate the dysfunctional ubiquitin-proteasome system. Defective functioning of VCP has been shown to result in accumulation of ubiquitin-positive inclusions both in human and mouse. 43, 54 Th ese fi ndings were consistent with our results further confi rming that the generated VCP R155H/+ mice represent a factual model for human disease. Another interesting fi nding in expression profi ling was the dysregulation of genes which are related to NF κ B signaling (SLC7A1/solute carrier family 7, member 1, CRISP3/unknown transcript, SLC3A1/solute carrier family 3, member 1, MEOX2/ mesenchyme homeobox 2, GADD45B/unknown transcript, TNFSF13B/tumor necrosis factor superfamily, member 13b, IKBKG/inhibitor of kappaB kinase gamma).
VCP has been shown to regulate NF-κ B signaling pathways by infl uencing the degradation process of cytoplasmic p-I κ B α , which has an antiapoptotic eff ect in cells. 55 Th erefore, the increased apoptosis observed in VCP R155H/+ mouse muscle may, at least partially, be explained by defective NF-κ B signaling. Th e third interesting fi nding in expression profi ling is the up-regulation of T-cell receptor beta (TRB), which is, in general, responsible for recognizing antigens bound to major histocompatibility complex molecules. Microarray analyses of other human myopathies (Inclusion body myositis, polymyositis, and dermatomyositis) demonstrate similar pronounced up-regulation of TRB in patients' muscle biopsies. More recently, Nalbandian et al. (2012) performed the fi rst global microarray analyses from patients' muscles with VCP mutations versus their fi rst-degree unaff ected and nonmutation carrying relatives. 28 Th is study elucidated several dysregulated signaling transduction pathways in VCP-associated diseases, including regulation of actin cytoskeleton, regulation of autophagy, ubiquitin/lysosomal, and cancer pathways. 28 In our comparative study between human and mouse microarrays, we did not fi nd a consistent pattern across genes that depicted common trends of dysregulation. We studied the literature to fi nd other investigations where microarray was performed in human disease and comparisons made with tissue from animal models of the same disease. Zheng-Bradley et al. (2010) analyzed data for each normal tissue in humans and mouse separately and found that the global patterns of tissue-specifi c expression of orthologous genes were conserved in human and mouse. 56 Th e most variable genes in each tissue were highly enriched with human-mouse tissue-specifi c orthologs and the least variable genes in each tissue were human-mouse housekeeping orthologs. 56 Another study by Chopra et al. (2013) investigated a comparative metaanalysis between human and mouse cancer microarray revealing critical pathways disrupted in both human and mouse cancers. 57 Watchmaker et al. investigated the transcriptional and functional profi ling in human and mouse intestinal dendritic cell subsets and identifi ed a few transcription factors whose expression was coordinately regulated, however, several factors represented divergence. 58 Similarly, in a study by Turk et al. (2005) in mdx mice and Duchenne muscular dystrophy patient muscle resembled our fi ndings. 59 A limited number of overlapping genes were identifi ed, with a number of genes showing opposite expression, suggested that processes active in regenerating mouse muscle are not active in human patients at the time gene expression was profi led, diff erences in regeneration effi ciency and lethal manifestation of the pathology between patients and murine muscles. 59 In conclusion, this is the fi rst study to investigate the signaling intermediates and transduction cascades in understanding VCPassociated disease in an excellent mouse model. Future studies will examine these dysregulated pathways and genes in both patients and VCP R155H/+ animals to elucidate and understand the pathological mechanisms underlying VCP-associated diseases in hopes of developing novel therapeutic interventions for these currently untreatable neurodegenerative diseases. Further investigations are underway to correlate human and mouse global microarray studies in hopes of better understanding of the pathological cellular and molecular mechanisms underlying VCP-related neurodegenerative disorders.
